Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC
Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).
Felip says that two groups of patients in the trial were treated with ceritinib. Of the 246 patients enrolled in the study, 83 patients were crizotinib-naïve and the rest were crizotinib-resistant. The study showed that the response rate was 72% in the patients that were crizotinib-naïve and 56% among the patients that were crizotinib-resistant.
More importantly, Felip says, patients that were crizotinib-naïve had a median progression-free survival of 18.4 months.